Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

1.54
-0.0700-4.35%
Volume:32.82K
Turnover:52.65K
Market Cap:5.49M
PE:-0.32
High:1.69
Open:1.69
Low:1.54
Close:1.61
52wk High:14.64
52wk Low:1.54
Shares:3.57M
Float Shares:3.14M
Volume Ratio:0.61
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8667
EPS(LYR):-6.6394
ROE:-275.16%
ROA:-125.93%
PB:1.34
PE(LYR):-0.23

Loading ...

Cadrenal Therapeutics - Appoints John P. Sharp as Interim CFO Effective June 25, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 30

Cadrenal Therapeutics - Quang X. Pham Ceases to Serve as Interim CFO - SEC Filing

THOMSON REUTERS
·
Jun 30

Cadrenal Therapeutics Names John P. Sharp Interim CFO, Replacing Quang X. Pham

Reuters
·
Jun 30

Cadrenal Therapeutics Chairman, CEO Quang X. Pham Reports Common Share Disposal Worth $33,807.45

Reuters
·
Jun 27

Cadrenal Therapeutics Chairman, CEO Quang X. Pham Sells USD 39,849 of Common Shares

Reuters
·
Jun 25

NASDAQ Trade Halt Volatility Trading Pause at 11:14 Am

Reuters
·
Jun 24

Cadrenal Therapeutics to Present Late-breaking Cad-1005 Phase 2 HIT Trial Data at ISTH Congress

Reuters
·
Jun 24

Cadrenal Therapeutics Announces Selection of Cad-1005 Phase 2 Study for Late-breaking Oral Presentation at Isth 2026 Congress

THOMSON REUTERS
·
Jun 24

Cadrenal Therapeutics Chairman, CEO and Interim CFO Quang X. Pham disposes of $13,127 in common shares

Reuters
·
Jun 19

Cadrenal plans FDA rare pediatric disease designation filing for tecarfarin in Kawasaki disease

Reuters
·
Jun 18

Cadrenal Therapeutics - to Submit FDA Rare Pediatric Disease Designation Request for Tecarfarin in Kawasaki Disease

THOMSON REUTERS
·
Jun 18

Cadrenal Therapeutics Chairman, CEO Quang X. Pham disposes of USD 70,947 in common shares

Reuters
·
Jun 16

Cadrenal Therapeutics to initiate CAD-1005 trial

TIPRANKS
·
Jun 15

Cadrenal Therapeutics plans Phase 2a trial of CAD-1005 to prevent acute kidney injury in high-risk cardiac surgery patients

Reuters
·
Jun 15

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (Csa-Aki) Clinical Plan to Accelerate Pharma Partnering at Upcoming Bio 2026

THOMSON REUTERS
·
Jun 15

Cadrenal Therapeutics - to Initiate Phase 2a Trial of CAD-1005 for Aki in Cardiac Surgery Patients

THOMSON REUTERS
·
Jun 15

Cadrenal Therapeutics - Phase 2a Trial Expected to Begin Later This Year

THOMSON REUTERS
·
Jun 15

Cadrenal Therapeutics CEO Quang X. Pham disposes of $90,610 common shares

Reuters
·
Jun 11

Cadrenal CEO, Chairman Quang X. Pham sells USD 36,071 of common shares

Reuters
·
Jun 06

BRIEF-Cadrenal Therapeutics Says Matthew Szot Steps Down As CFO - SEC Filing

Reuters
·
Jun 04